Chrome Extension
WeChat Mini Program
Use on ChatGLM

Primary Prophylaxis with G-CSF May Improve Outcomes in Patients with Newly Diagnosed Stage III/IV Hodgkin Lymphoma Treated with Brentuximab Vedotin Plus Chemotherapy

Leukemia & lymphoma(2020)SCI 4区

Mem Sloan Kettering Canc Ctr | Churchill Hosp | Maria Sklodowska Curie Mem Inst & Oncol Ctr | Univ Bologna | Austin Hosp | Hosp Quiron Dexeus | Univ Debrecen | Seoul Natl Univ Hosp | Petrov Res Inst Oncol | Univ Copenhagen | Univ Sao Paulo | BC Canc Ctr Lymphoid Canc | Seattle Genet | Millennium Pharmaceut Inc | Antoine Lacassagne Canc Ctr

Cited 11|Views87
Abstract
We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP,N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHELON-1 study of previously untreated stage III/IV classical Hodgkin lymphoma. G-PP was associated with lower incidence of >= grade 3 neutropenia (29% versus 70%) and febrile neutropenia (11% versus 21%). Fewer dose delays (35% versus 49%), reductions (20% versus 26%), and hospitalizations (29% versus 38%) were observed. Seven neutropenia-associated deaths occurred in the A + AVD arm; none received G-PP. A + AVD with G-PP was associated with decreased risk of a modified progression-free survival event by 26% compared with A + AVD alone (95% CI: 0.40-1.37). G-PP reduced the rate and severity of adverse events, including febrile neutropenia, reduced treatment delays, dose reductions, and discontinuations, and may thus improve efficacy outcomes. These data support G-PP for all patients treated with A + AVD.
More
Translated text
Key words
Hodgkin lymphoma,brentuximab vedotin,frontline therapy,growth factor,primary prophylaxis
PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
REN VANRIJSWIJK, C HAANEN, AW DEKKER, AJ DEMEIJER,J VERBEEK
1989

被引用86 | 浏览

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:该研究调查了在接受brentuximab vedotin联合化疗治疗的新诊断III/IV期霍奇金淋巴瘤患者中,应用粒细胞集落刺激因子(G-CSF)作为一级预防对安全性和有效性的影响,发现G-CSF的一级预防能改善治疗结果。

方法】:研究者对ECHELON-1研究中,未经治疗的III/IV期经典霍奇金淋巴瘤患者进行了G-CSF一级预防(G-PP)与无G-PP的比较。

实验】:在该实验中,与无G-PP组相比,G-PP组患者≥ grade 3中性粒细胞减少症和发热性中性粒细胞减少症的发生率更低,剂量延迟、减少和住院率也相应减少。G-PP组与无G-PP组相比,改良的无进展生存事件风险降低了26%。G-PP减少了不良事件的发生率和严重程度,包括发热性中性粒细胞减少症、治疗延迟、剂量减少和中断,这可能改善了疗效结果。这些数据支持在所有接受A+AVD治疗的病人中使用G-PP。